Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemaira in Steroid Refractory Acute GVHD
NCT01700036Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2013
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of alpha1-proteinase inhibitor in graft-versus-host disease (GVHD), sponsored by University of Michigan Rogel Cancer Center. Started Jul 2013; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01700036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01700036.